BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 17540602)

  • 1. Manufacture of plasma-derived products in France and measures to prevent the risk of vCJD transmission: precautionary measures and efficacy of manufacturing processes in prion removal.
    Flan B; Arrabal S
    Transfus Clin Biol; 2007 May; 14(1):51-62. PubMed ID: 17540602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies to prevent transmission of prions by human plasma derivatives.
    Burnouf T; Padilla A
    Transfus Clin Biol; 2006 Nov; 13(5):320-8. PubMed ID: 17254822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
    Farrugia A; Ironside JW; Giangrande P
    Vox Sang; 2005 Nov; 89(4):186-92. PubMed ID: 16262750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion-transmitted variant Creutzfeldt-Jakob disease.
    Cervia JS; Sowemimo-Coker SO; Ortolano GA; Wilkins K; Schaffer J; Wortham ST
    Transfus Med Rev; 2006 Jul; 20(3):190-206. PubMed ID: 16787827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products.
    Ludlam CA; Turner ML
    Br J Haematol; 2006 Jan; 132(1):13-24. PubMed ID: 16371015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transfusion transmission of human prion diseases.
    Zou S; Fang CT; Schonberger LB
    Transfus Med Rev; 2008 Jan; 22(1):58-69. PubMed ID: 18063192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products.
    Ironside JW; Head MW
    Haemophilia; 2004 Oct; 10 Suppl 4():64-9. PubMed ID: 15479374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus statement on the bio-safety of urinary-derived gonadotrophins with respect to Creutzfeldt-Jakob disease.
    Balen AH; Lumholtz IB
    Hum Reprod; 2005 Nov; 20(11):2994-9. PubMed ID: 16055457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ['Variant of Creutzfeldt-Jacob disease and blood transfusion'; report of the Dutch Health Council].
    van Aken WG
    Ned Tijdschr Geneeskd; 2001 Jul; 145(30):1444-7. PubMed ID: 11503311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [vCJD epidemiology in France].
    Brandel JP; Salomon D; Alpérovitch A
    Transfus Clin Biol; 2006 Nov; 13(5):304-6. PubMed ID: 17188544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The risk of prion contamination through the transfusion of cellular products].
    Lefrère JJ
    Transfus Clin Biol; 2007 May; 14(1):25-34. PubMed ID: 17499536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSE clearance during plasma products separation process by Gradiflow(TM).
    Wang K; Johnson A; Obradovic M; Anderson G; Maclean C; Nair H
    Biologicals; 2005 Jun; 33(2):87-94. PubMed ID: 15939286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prions and transfusion medicine.
    Budka H
    Vox Sang; 2000; 78 Suppl 2():231-8. PubMed ID: 10938959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of transmission of Creutzfeldt-Jakob disease via blood and blood products. The French risk-analysis over the last 15 years.
    Martin M; Trouvin JH
    Transfus Clin Biol; 2013 Sep; 20(4):398-404. PubMed ID: 23910008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of accidental transmission of transmissible spongiform encephalopathy: identification of emerging issues.
    Ramasamy I
    Public Health; 2004 Sep; 118(6):409-20. PubMed ID: 15313594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From mad cows to sensible blood transfusion: the risk of prion transmission by labile blood components in the United Kingdom and in France.
    Lefrère JJ; Hewitt P
    Transfusion; 2009 Apr; 49(4):797-812. PubMed ID: 19170997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance of prions during plasma protein manufacture.
    Burdick MD; Pifat DY; Petteway SR; Cai K
    Transfus Med Rev; 2006 Jan; 20(1):57-62. PubMed ID: 16373188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variant Creutzfeldt-Jakob disease in a transfusion recipient: coincidence or cause?
    Chohan G; Llewelyn C; Mackenzie J; Cousens S; Kennedy A; Will R; Hewitt P
    Transfusion; 2010 May; 50(5):1003-6. PubMed ID: 20230536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expert elicitation for the judgment of prion disease risk uncertainties.
    Tyshenko MG; ElSaadany S; Oraby T; Darshan S; Aspinall W; Cooke R; Catford A; Krewski D
    J Toxicol Environ Health A; 2011; 74(2-4):261-85. PubMed ID: 21218351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.